Kick-off meeting on Feb 24, 2022 for ISIDORe, a meta-infrastructure of unprecedented dimension to fight COVID19 and future pandemics

EU-OPENSCREEN leads a transnational access work package dedicated to diagnostic and therapeutic discovery services in the ISIDORe project a meta-infrastructure of unprecedented dimension which was kicked off last week with the goal to fight COVID-19 and future Pandemics.

What is ISIDORe?

ISIDORe is an EU-funded project under the Horizon Europe program that unites a multidisciplinary consortium of 17 European research infrastructures to offer integrated services for combatting current and future infectious disease outbreaks. It is coordinated by our partner research infrastructure ERINHA. ISIDORe brings together more than 150 European service providers from 32 countries and a total funding of €21 million. The project provides access to key services to support projects for the study of SARS-CoV-2, its variants and other potential pathogens. ISIDORe is part of the EU-Commission´s biodefense preparedness plan, the Health Emergency Preparedness and Response Authority (HERA) Incubator. Considering its structure, it represents a meta-infrastructure project of unprecedented dimensions in the European Research Area and serves as a central instrument in the European R&D response to epidemic outbreaks.

You can read more about the launch of Europe's Integrated Services For Infectious Disease Outbreak Research here:

What is EU-OPENSCREEN´s involvement in ISIDORe?

EU-OPENSCREEN ERIC as the European Research Infrastructure Consortium for chemical biology and early drug discovery leads a transnational access work package dedicated to diagnostic and therapeutic discovery services. EU-OPENSCREEN screening and chemistry partner sites offer drug discovery and early preclinical development services to external researchers in academia and industry working on new therapeutics against SARS-CoV-2 variants and epidemic-prone pathogens. Activities range from assay development and validation of preliminary research results, to HTS hit discovery programs using high throughput in vitro biochemical and cell-based assays to further progress promising small molecules to lead development and candidate nomination stage.

Moreover, EU-OPENSCREEN teams up with European partners that offer access to antibody and nanobody discovery platforms, and to services related to the development of in vitro diagnostic tests. The overall aim is to build and integrate an efficient and fast service platform that accommodates the broad demands of users seeking small molecule and antibodies therapeutics as well as diagnostic solutions.

Who is participating?

In ISIDORe diagnostic and therapeutic discovery services will be provided by a network of multiple access providers:

  • EU-OPENSCREEN HTS screening sites for small molecule drug discovery: Fundacion Medina (ES), Palacký University Olomouc, Institute of Molecular and Translational Medicine (CZ), Institute of Molecular Genetics AS CR (CZ), University of Helsinki (UH), Helmholtz Centre for Infection Research, Chemical Biology Department (DE), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), SINTEF (NO), University of Oslo, Centre for Molecular Medicine (NO), Institute of Bioorganic Chemistry (IBCH), Polish Academy of Science (PL).
  • EU-OPENSCREEN medicinal chemistry and early preclinical facilities for small molecule drug discovery: Latvian Institute of Organic Synthesis (LV), Center for Biological Research Margarita Salas, CSIC (ES), Institute of Biochemistry and Biophysics (PL), Technical University of Denmark (DK), Leibniz Research Institute for Molecular Pharmacology (DE).
  • BSL3/BSL4 HTS capacity with infectious live virus: Katholieke Universiteit Leuven, Rega Institute for Medical Research (BE)
  • Antibody/nanobody discovery platforms: Fondazione per l'istituto di ricerca in biomedicina, IRB (CH), Institute of Biochemistry and Biophysics (PL), Maria Sklodowska-Curie National Research Institute of Oncology (PL), Medical University of Warsaw (PL), and EC Joint Research Centre (JRC)
  • New microfluidic devices for distinguishing viral variants based on nucleic acids and antibodies are developed by the Biomedical Research Foundation, Academy of Athens (GR), and the Joanneum Research (AT)

Open calls to access EU-OPENSCREEN facilities, antibodies discovery platforms and diagnostic services will be announced on our webpage. Information about our screening and chemistry partners can be found at and, respectively.

Read more here.

How can you contact us if you wish to collaborate with us, or would like to get more information on the ISIDORe project?

Please use the contact form on our website here or contact our Scientific Project Manager Tanja Miletić, E-Mail: for further information.